Pennsylvania: The State of HCV 2015

Slides:



Advertisements
Similar presentations
Specific issues and guidelines for HCV treatment in IDUs Bern d Schulte Centre for Interdisciplinary Addiction Research (CIAR), University Hamburg.
Advertisements

Hepatitis web study H EPATITIS W EB S TUDY Hepatitis A: Epidemiology Presentation Prepared by: David Spach, MD and Nina Kim, MD Last Updated: May 31, 2011.
Hepatitis C In Alaska’s Department of Corrections
HIV Prevention, treatment and care among people who inject drugs Fabienne Hariga, MD, MPH Senior HIV Adviser, UNODC Vienna.
Global Hepatitis C Guidelines 2014: recommendations for a public health approach Gottfried Hirnschall.
Hepatitis C Rapid Antibody Testing Among At-Risk Populations, Arizona, 2014 Felicia McLean Public Health Associate Office for State, Tribal, Local and.
Hepatitis and Liver Cancer A National Strategy for Prevention and Control of Hepatitis B and C.
Hepatitis web study H EPATITIS W EB S TUDY Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance.
Incorporating HIV and Viral Hepatitis Testing and Referral into Idaho Drug Court Programs Presented by Idaho Advisory Council on HIV and AIDS, Bebe Thompson,
Afghanistan’s Present IDUs-HIV/AIDS Situation and future action plan Dr.Saifur-Rehman NACP Director April,11,2007 Islamic Republic of Afghanistan Ministry.
Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIV/AIDS, Viral Hepatitis,
HIV and Behavioral Health: An Update from SAMHSA Elinore F. McCance-Katz, MD, PhD Chief Medical Officer Substance Abuse and Mental Health Services Administration.
HIV and drug prevention in Estonia Harm reduction services
Module 3: HCV prevalence and course of HCV infection.
Morbidity Monitoring Project Data for Resource Planning and Evaluation A.D. McNaghten Centers for Disease Control and Prevention.
Larry Cuellar Adult Viral Hepatitis Prevention Coordinator Texas Department of State Health Services 2010 STREET OUTREACH WORKERS CONFERENCE June 21, 2010.
Harm Reduction.
Overview of Harm Reduction and Sterile Syringe Access Anna Benyo Syringe Access Policy Coordinator Harm Reduction Coalition New Jersey Syringe Access Informational.
Working with SEPs: How do we expand Hepatitis Services ? Narelle Ellendon, RN HCV Director Harm Reduction Coalition, NYC
INJECTION DRUG USE IN METROPOLITAN CINCINNATI Judith Feinberg, MD Professor of Medicine University of Cincinnati College of Medicine November 12, 2012.
HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania Signe ROTBERGA UNODC, Baltic States 5 November.
A Cluster of Hepatitis C among Rural, Young Adults – Illinois, 2012 Julia Howland, MPH CPH CDC/CSTE Applied Epidemiology Fellow Illinois Department of.
Co-occurring Challenges: Leveraging ADAP and ACA to Address Hepatitis C and Substance Use Disorders Daniel Raymond Policy Director Harm Reduction Coalition.
Using HIV Surveillance to Achieve High Impact Prevention Irene Hall, PhD, FACE AIDS 2012 High-Impact Prevention: Reducing the HIV Epidemic in the United.
Kevin Fenton, MD, PhD National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention August 5, 2008 Update on the US HIV/AIDS Crisis: Current Trends,
TB, STDs, HIV, HEPATITIS C and SUBSTANCE ABUSE: A Local Perspective Paula Kriner, MPH Imperial County Public Health Department Management of TB, STDs,
HIV Care Continuum Persons Living With HIV, Georgia, 2012.
Introduction to NCHHSTP National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Office of the Director Jonathan Mermin, MD, MPH National.
Olivia Chang, MPH Research and Program Manager Pangaea Global AIDS
Injection Drug Use and Hepatitis C What Can We Do About It? Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse.
Decline in incidence of HIV and Hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? 1. Julius Center, University.
Hepatitis C: The Silent Epidemic Wednesday, October 21, 2015 John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention.
Jennifer R. Havens, PhD, MPH Associate Professor
Diane M. Janowicz, MD Assistant Professor of Clinical Medicine Indiana University School of Medicine Indianapolis, Indiana Persistent Challenges of HIV.
Prevention, Treatment and Care of Hepatitis C among People Who Inject Drugs Jason Grebely, PhD Senior Lecturer Viral Hepatitis Clinical Research Program.
Bringing Hepatitis C Treatment into the Medical Home A Pilot Program for Drug Users Dr. Joanna Eveland MS, MD, Clinical Chief for Special Populations Mission.
Lessons Learned and Novel Investigation Techniques in Response to a Large Community Outbreak of HIV-1 infection Philip J. Peters MD HIV Testing and Biomedical.
IDUHA Hepatitis C Peer Navigation Program Brooklyn Hep C Task Force Meeting Brooklyn Borough Hall March 9, 2016 Viral Hepatitis Surveillance, Prevention.
Lessons from Indiana HIV and Hepatitis C Wisconsin HIV Community Planning Statewide Action Planning Group Meeting Green Lake June 25,
Trends in the Prevalence of Hepatitis C and Hepatitis B and HIV in Seattle Injection Drug Users, 18 – 30 years old, Richard Burt, Holly Hagan,
Innovative Strategies for Addressing Hepatitis C in Indian Country March 14, 2016.
Health in Prisons Project Oslo, 24 November 2009 Lars Moller Regional Adviser a.i. World Health Organization Regional Office for Europe Health in Prisons.
Services and C Leon Wylie Lead Officer Hepatitis Scotland.
Current state of HIV and associated infections epidemic among adolescents and youth: LATVIA Anda Karnite, MPH, PHD Riga Stradins University and Baltic.
Behavioral Health and HIV/HCV Risk Behavior Among Young African American IDUs Patricia M Morse, LCSW, PhD, Edward V, Morse, PhD, Samuel Burgess, MA, MPH.
Non-Medical Staff Knowledge, Beliefs and Practices about HIV and Hepatitis for Injection Drug Users Rowe, KA 1, Tesoriero, JM 1, Heavner, KK 1, Rothman,
Diane M. Janowicz, MD Assistant Professor of Clinical Medicine Indiana University School of Medicine Indianapolis, Indiana Persistent Challenges of HIV.
An Overview for Healthcare Providers
State Office of AIDS Update
Hepatitis C Surveillance: From nothing to something...
Addressing Viral Hepatitis
Charlie Howsare, MD MPH Pa. Viral Hepatitis Prevention Coordinator
Cascade of care for people who use drugs - opportunities for integration and scale up of harm reduction services and other evidence based interventions.
An Overview for Healthcare Providers
Hepatitis C Incidence and Prevalence in the U.S.
No one gets left behind: Addressing the hidden burden of hepatitis C related advanced liver disease in PWID in the community John S Lambert, MD, PhD.
Rowe, KA1, Tesoriero, JM1, Davis, SJ1, Heavner, KK1, Rothman, J2,
Summary Report: Management of Hepatitis C in Prisons
Viral Hepatitis in Correctional Settings
Lesson 4: Preventing HCV Reinfection
Jonathan Mermin, MD, MPH RADM, USPHS
World Epidemiology. Are HIV and Other Chronic Diseases Models Applicable to Viral Hepatitis? Focus on HCV.
HCV Screening.
HCV epi overview Brigg Reilley, NPAIHB,
Hepatitis C Tennessee Caring Ambassadors, Senate Briefing May 18, 2018
ENDING THE EPIDEMICS: A FOCUS ON PEOPLE WHO INJECT DRUGS
No conflicts of interest
Lesson 3: Treatment as Prevention
Human Dignity and Harm Reduction
Managing Hepatitis C in Vermont
Presentation transcript:

Pennsylvania: The State of HCV 2015 Charlie Howsare, MD MPH Pa. Viral Hepatitis Prevention Coordinator

Introduction Baby Boomers Sentinel Events Overdose deaths Outbreak in Indiana 400% increase in HCV in 4 States EPI studies using geospatial overlays Continuum of care Interventions Summary

Prevalence of Current HCV Infection among U.S. Population ~3 million people with current infection National Health and Nutrition Examination Survey (NHANES) prevalence estimate 2.7 million persons (2.2-3.2 million) 1.0% of general U.S. population (0.8%-1.2%) Civilian, non-institutionalized populations Non-NHANES prevalence estimate 500,000 persons(360,000-840,000) Incarcerated population (15-35% HCV prevalence) Homeless persons Denniston M, Ann Int Med 2014; Chak E, Liver Int 2011; Weinbaum MMWR, 2003

Sentinel Events Overdose deaths HIV/HCV Outbreak in Indiana 400% increase in HCV in 4 States Tripling of heroin users

HCV Infection from Injection Drug Use Behaviors Injection drug use (IDU) is the principle risk factor for HCV infection Most reported risk behavior in acute case reporting HCV prevalence among persons who inject drugs (PWID) between 30% and 70% HCV prevalence among younger (<30 yrs.) between 10% and 36% HCV incidence between 16% and 42% per year Hagan et al. 2010; Garfein et al. 1998; Armstrong et al. 2006; Amon et al. 2008; Klevens et al. 2013; Daniels et al. 2007

Increases in New HCV Infections 50% increase in national reporting 200% increase in 17 states Recent studies show ~ 70% report IDU Ages 18 to 29 years Predominantly white Equally female and male Non-urban and urban Antecedent presc opioid misuse 2007-2012 Source: CDC/hepatitis.gov; MMWR 2011; MMWR 2014; CDC unpublished data.

PA-NEDSS Reported HCV Past and Present by Age Group

Changes in Demographics PA 2003 2007

Changes in Demographics PA 2010 2014

GIS Mapping of HCV Age-Specific per 100,000 for the 15-35 year old demographic

HCV Care Continuum

Necessary but not sufficient…. Drug Treatment with MAT Methadone Suboxone Harm Reduction Syringe/works exchange Naloxone HCV treatment Reduce the viral load of the using community

Framework of a model HCV control strategy for PWID Prevent new infections Detect and care for existing infections Reduce chronic infections HCV prevention activities Access to syringes & other equipment OST Safe injection education Outreach to those not engaged Screening and diagnosis Antibody screening RNA test to confirm infection Clinical evaluation to determine disease stage Monitoring disease progression Reduce alcohol use HCV care and treatment Treat to cure infection Support adherence to treatment Support post-cure to prevent reinfection Co-locating these services increases their impact on HCV control 7 Provided by Holly Hagan

Multi-Component Interventions An approach to risk reduction where syringe exchange programs (SEP) and opioid agonist therapy (OAT) programs are combined as “packages” and offered concurrently in the form of a “one-stop shop.” A combination of readily-available and low threshold OAT (with methadone and/or buprenorphine) and SEPs have been shown to: Reduce syringe sharing Lower injecting risk Reduce incidence of HIV and HCV Up to 80% in UK Three fold - New York

Hepatitis C: The “Silent Epidemic” 6 seminars with CME Organized by stakeholders in the region with assistance from VHPC Focus on young adult IDUs Provide an atmosphere for cooperation, collaboration, and relationship building

HCV Resource Guide 2 interns per region External SharePoint site for document sharing Web-based, searchable Use seminar contacts and participants to build the HCV Resource Guide Create informal care networks https://extsharepoint.health.pa.gov/sites/HepCRGP/SitePages/Home.aspx

Mini-Grant HCV Testing Sites Harm reduction Drug and alcohol treatment facilities Medical facilities HIV clinics Free Rapid HCV Ab test kits Share linkage to care data back with us

Summary EPI studies using geospatial overlays Continuum of care Interventions Community health districts CME educational seminars HCV Resource Guide Rapid HCV Ab mini-grants Summary